Sponsor or institution

Clinical trials and research at Hoffmann-La Roche

• 78Clinical trials
• 61Countries

Newest trials

All recruiting trials (78)

• Afimkibart subcutaneous induction in moderately to severely active ulcerative colitis

  This study tests whether a subcutaneous induction dose of afimkibart can help people with moderately to severely active ulcerative colitis feel better compared with placebo.

  Recruiting Phase 3 Hoffmann-La Roche · Cordova, Tennessee · NCT07846683

• Petrelintide for weight management in adults with overweight or obesity

  This study tests whether petrelintide helps people with overweight or obesity lose weight when combined with a reduced-calorie diet and more exercise, compared with a placebo.

  Recruiting at 8 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 7 other locations · NCT07843498

• Petrelintide for weight management in adults with overweight/obesity and type 2 diabetes

  This study tests whether petrelintide, added to a reduced-calorie diet and more physical activity, helps people with overweight or obesity and type 2 diabetes lose weight more effectively than a placebo.

  Recruiting at 2 sites Phase 3 Hoffmann-La Roche · Los Angeles, California and 1 other locations · NCT07843485

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• Baloxavir for preventing flu after exposure in household contacts

  A single dose of baloxavir marboxil is being tested to see if it prevents symptomatic, lab-confirmed influenza in people who live with someone who has flu symptoms.

  Recruiting at 8 sites Phase 3 Hoffmann-La Roche · Guangzhou, Guangdong and 7 other locations · NCT07827599

• People with Relapsing-Remitting MS try subcutaneous ocrelizumab at their clinic

  This study looks at how satisfied people with relapsing-remitting MS feel about receiving subcutaneous ocrelizumab in routine care.

  Recruiting at 2 sites Hoffmann-La Roche · Pardubice, Pardubice Region and 1 other locations · NCT07827586

• Giredestrant in ER-positive, HER2-negative early breast cancer: who tolerates it and sticks with treatment

  This study tests how well people with ER-positive, HER2-negative early breast cancer can tolerate and stay on giredestrant, and how they feel during treatment.

  Recruiting Phase 3 Hoffmann-La Roche · Québec, Quebec · NCT07827573

• Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma

  This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.

  Recruiting at 5 sites Phase 2 Hoffmann-La Roche · Nuremberg, Bavaria and 4 other locations · NCT07825064

• RO7830698 in healthy people and COPD patients

  This study tests RO7830698 to see if it is safe and how it behaves in the body for healthy individuals and people with COPD.

  Recruiting Phase 1/2 Hoffmann-La Roche · Wythenshawe, Greater Manchester · NCT07822334

• Test of RO7568282 vs placebo in early Alzheimer's disease

  This study tests whether RO7568282 can help people in the early stages of Alzheimer's disease compared with a placebo.

  Recruiting at 7 sites Phase 2 Hoffmann-La Roche · Stuart, Florida and 6 other locations · NCT07781657

• Test of RO7568282 in early Parkinson's disease

  This study tests whether RO7568282, compared with placebo, is safe and helps people with early Parkinson's disease who are already taking levodopa.

  Recruiting at 4 sites Phase 2 Hoffmann-La Roche · Boca Raton, Florida and 3 other locations · NCT07781644

• Inavolisib plus Fulvestrant with or without Palbociclib in PIK3CA-mutated HR+/HER2- Advanced Breast Cancer and Type 2 Diabetes

  This study tests whether adding inavolisib to fulvestrant, with or without palbociclib, is safe for people with PIK3CA-mutated, HR+, HER2-negative advanced breast cancer and type 2 diabetes.

  Recruiting at 10 sites Phase 2 Hoffmann-La Roche · Washington D.C., District of Columbia and 9 other locations · NCT07748208

• Safety and how the body handles RO7795081 in people with kidney problems

  This study tests how RO7795081 behaves in the body and its safety after a single dose in people with normal kidney function and those with renal impairment.

  Recruiting at 3 sites Phase 1 Hoffmann-La Roche · Miami Lakes, Florida and 2 other locations · NCT07741604

• Trontinemab to see if it helps people at risk for Alzheimer’s disease progress

  This study tests whether trontinemab can help people who have biomarker signs of Alzheimer’s disease but no symptoms yet.

  Recruiting at 72 sites Phase 3 Hoffmann-La Roche · Irvine, California and 71 other locations · NCT07717411

• Enicepatide in people who are overweight or obese, with or without Type 2 diabetes

  This study tests whether enicepatide helps people who are overweight or have obesity, with or without Type 2 diabetes, lose weight when added to a reduced-calorie diet and more activity.

  Recruiting at 21 sites Phase 3 Hoffmann-La Roche · Zhengzhou, Henan and 20 other locations · NCT07670416

• How afimkibart may affect medicine processing in people with active ulcerative colitis

  This early-stage study tests whether afimkibart changes how the body processes several common drugs in people with moderately to severely active ulcerative colitis.

  Recruiting at 18 sites Phase 1 Hoffmann-La Roche · Chula Vista, California and 17 other locations · NCT07665723

• Long-term safety and effectiveness of Afimkibart in rheumatoid arthritis patients who previously used Afimkibart

  This study tests whether Afimkibart can continue to be safe and helpful for people with moderate to severe rheumatoid arthritis who previously showed improvement or who didn’t tolerate TNF or JAK inhibitors.

  Recruiting at 12 sites Phase 2 Hoffmann-La Roche · Tamarac, Florida and 11 other locations · NCT07620392

• Mosunetuzumab for people with systemic lupus erythematosus

  This study tests mosunetuzumab in people with systemic lupus erythematosus, with or without active lupus nephritis.

  Recruiting at 24 sites Phase 2 Hoffmann-La Roche · CABA, Buenos Aires and 23 other locations · NCT07598396

• RO7663498 eye injection safety in diabetic retinopathy

  This study tests the safety, tolerability, and how the drug behaves in the body after an intravitreal injection for people with diabetic retinopathy.

  Recruiting at 4 sites Phase 1 Hoffmann-La Roche · Glendale, California and 3 other locations · NCT07588100

• Cevostamab with pomalidomide and dexamethasone vs standard care in previously treated multiple myeloma

  This study tests whether adding cevostamab to pomalidomide and dexamethasone helps people with multiple myeloma who have already had some prior treatments and exposure to anti-CD38 therapy and lenalidomide.

  Recruiting at 103 sites Phase 3 Hoffmann-La Roche · Duarte, California and 102 other locations · NCT07555938

• Divarasib vs investigator’s choice of immunotherapy or observation after resection in KRAS G12C NSCLC

  This study tests whether divarasib works better than your doctor’s preferred immunotherapy or observation for people with resected KRAS G12C-positive NSCLC who did not reach complete response after prior neoadjuvant therapy.

  Recruiting at 103 sites Phase 3 Hoffmann-La Roche · Clovis, California and 103 other locations · NCT07541170

• Risdiplam in Type I and Type II Spinal Muscular Atrophy: real-world outcomes

  This real-world study looks at how risdiplam works and its safety in children with Type I or Type II SMA over about two years.

  Recruiting at 2 sites Hoffmann-La Roche · Cairo and 1 other locations · NCT07531719

• Treatment patterns and adherence after decentralizing care for early HER2-positive breast cancer

  This study tests whether moving adjuvant HER2-targeted treatment closer to patients helps people with early-stage HER2-positive breast cancer stick to their therapy.

  Recruiting at 10 sites Hoffmann-La Roche · Loznica, Bolnička 65 and 9 other locations · NCT07527741

• Blood test to help diagnose, predict outcomes, and monitor traumatic brain injury in adults

  This project will try a blood test to help diagnose and predict outcomes for adults with non-penetrating traumatic brain injury and to monitor for secondary problems while they are hospitalized.

  Recruiting at 6 sites Hoffmann-La Roche · Sacramento, California and 13 other locations · NCT07455136

• NXT007 versus emicizumab to prevent bleeds in people with Hemophilia A

  This will test whether NXT007 prevents bleeding better than emicizumab in people aged 12 and older with Hemophilia A, including those with or without factor VIII inhibitors.

  Recruiting at 63 sites Phase 3 Hoffmann-La Roche · Orange, California and 62 other locations · NCT07416604

• CEA-PRIT 2.0 for metastatic colorectal cancer

  This trial will test CEA-PRIT 2.0, a targeted pretargeted radioligand treatment using split antibodies and lead-based payloads, in people with metastatic microsatellite-stable colorectal cancer who have progressed on or cannot tolerate standard therapies.

  Recruiting at 5 sites Phase 1 Hoffmann-La Roche · Chicago, Illinois and 4 other locations · NCT07416552

• Comparing NXT007 injections with Factor VIII prophylaxis for people with moderate-to-severe hemophilia A

  This will see if regular NXT007 injections prevent bleeds better than standard Factor VIII prophylaxis in people aged 12 and older with moderate-to-severe hemophilia A who do not have FVIII inhibitors.

  Recruiting at 36 sites Phase 3 Hoffmann-La Roche · Aurora, Colorado and 35 other locations · NCT07416526

• RO7771950 versus tucatinib with trastuzumab and capecitabine for HER2-positive locally advanced or metastatic breast cancer

  This test will see if RO7771950 combined with trastuzumab and capecitabine works better than tucatinib combined with the same drugs for people with HER2-positive locally advanced or metastatic breast cancer.

  Recruiting at 219 sites Phase 2/3 Hoffmann-La Roche · Huntsville, Alabama and 218 other locations · NCT07413939

• Adding inavolisib to ribociclib and fulvestrant for HR+ HER2- advanced breast cancer with chr8p loss

  This trial tests whether adding inavolisib to ribociclib and fulvestrant helps people with endocrine‑therapy‑resistant HR+ HER2‑ advanced breast cancer who have chromosome 8p loss and no PIK3CA mutation.

  Recruiting at 59 sites Phase 2 Hoffmann-La Roche · Anaheim, California and 58 other locations · NCT07405801

• Inavolisib plus fulvestrant for PIK3CA‑mutated HR‑positive, HER2‑negative advanced breast cancer after CDK4/6 inhibitors

  This tests whether adding inavolisib to fulvestrant helps people with PIK3CA‑mutated, hormone receptor–positive, HER2‑negative locally advanced or metastatic breast cancer whose disease progressed after CDK4/6 inhibitor therapy.

  Recruiting at 34 sites Phase 2 Hoffmann-La Roche · Los Angeles, California and 33 other locations · NCT07368998

• Enicepatide for weight management in people with overweight or obesity and type 2 diabetes

  This trial tests whether enicepatide helps adults with overweight or obesity and type 2 diabetes lose weight compared with a placebo.

  Recruiting at 222 sites Phase 3 Hoffmann-La Roche · Guntersville, Alabama and 221 other locations · NCT07351058

• Enicepatide for weight loss in adults with overweight or obesity without Type 2 diabetes

  This study will test whether different doses of enicepatide help adults with overweight or obesity who do not have Type 2 diabetes lose weight compared with placebo and are safe.

  Recruiting at 209 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 208 other locations · NCT07351045

• Inavolisib-based treatment for endocrine-resistant PIK3CA-mutated HR+/HER2- advanced breast cancer

  This trial tests an inavolisib-based regimen in people in China who have endocrine-resistant, PIK3CA-mutated, hormone receptor–positive, HER2‑negative locally advanced or metastatic breast cancer after finishing adjuvant endocrine therapy.

  Recruiting at 32 sites Hoffmann-La Roche · Xiamen, Fujian and 31 other locations · NCT07347600

• Afimkibart for children with moderate to severe Crohn's disease

  This phase 3 trial tests Afimkibart to see if it helps children with moderately to severely active Crohn's disease while measuring safety.

  Recruiting at 19 sites Phase 3 Hoffmann-La Roche · New York, New York and 18 other locations · NCT07298421

• Inavolisib plus enzalutamide for metastatic castration-resistant prostate cancer

  This phase 2 trial will test whether adding inavolisib to enzalutamide helps biomarker-selected patients with metastatic castration-resistant prostate cancer who have already received one second-generation androgen-receptor pathway inhibitor.

  Recruiting at 50 sites Phase 2 Hoffmann-La Roche · Los Angeles, California and 49 other locations · NCT07287150

• Atezolizumab subcutaneous: patient satisfaction, effectiveness, and safety in routine care

  This will see if subcutaneous Atezolizumab given in routine care is satisfying, helpful, and safe for people with certain types of lung cancer or advanced liver cancer.

  Recruiting at 92 sites Hoffmann-La Roche · Krems and 91 other locations · NCT07284121

• Adding RO7268489 to ocrelizumab for progressive multiple sclerosis

  This trial will test whether adding RO7268489 to ocrelizumab helps adults with progressive multiple sclerosis.

  Recruiting at 114 sites Phase 2 Hoffmann-La Roche · Camperdown, New South Wales and 113 other locations · NCT07282574

• Testing the safety and body effects of RO7806881 in healthy adults

  This study will test single and multiple doses of RO7806881 in healthy adults to see if the drug is safe and how the body absorbs, distributes, and responds to it.

  Recruiting Phase 1 Hoffmann-La Roche · Christchurch · NCT07271693

• SPK-8011QQ gene therapy for adults with severe or moderately severe hemophilia A

  This trial will test a one-time gene therapy called SPK-8011QQ in adult men with severe or moderately severe hemophilia A to see if it is safe and well tolerated.

  Recruiting at 6 sites Phase 1/2 Hoffmann-La Roche · Orange, California and 5 other locations · NCT07226206

• Glofitamab for Chinese adults with second-line relapsed or refractory diffuse large B‑cell lymphoma

  This will test whether glofitamab-based therapy helps and is safe for Chinese adults whose diffuse large B‑cell lymphoma returned or didn't respond after one prior treatment.

  Recruiting at 22 sites Hoffmann-La Roche · Langfang, Hebei and 21 other locations · NCT07200375

• Screening to identify people who may qualify for Alzheimer's disease clinical programs

  This screening process tries to find people with recent memory concerns, mild cognitive impairment, or early Alzheimer's who may be eligible for Roche interventional Alzheimer's trials.

  Recruiting at 166 sites Phase 3 Hoffmann-La Roche · Birmingham, Alabama and 233 other locations · NCT07177352

• IV prasinezumab treatment for people with early-stage Parkinson's disease

  This study will try IV prasinezumab versus placebo in people with early-stage Parkinson's disease who are on stable levodopa monotherapy.

  Recruiting at 183 sites Phase 3 Hoffmann-La Roche · Birmingham, Alabama and 191 other locations · NCT07174310

• Fenebrutinib for relapsing multiple sclerosis in children and adolescents (ages 10 to <18).

  This study will test fenebrutinib in children and adolescents ages 10 to under 18 with relapsing multiple sclerosis to measure how the drug behaves in the body and whether it is safe and well tolerated.

  Recruiting at 17 sites Phase 2 Hoffmann-La Roche · Rosario, Santa Fe Province and 16 other locations · NCT07161258

• Afimkibart for children with moderately to severely active ulcerative colitis

  This Phase III study will try Afimkibart to see if it helps children with moderate to severe ulcerative colitis and is safe for them.

  Recruiting at 29 sites Phase 3 Hoffmann-La Roche · Aurora, Colorado and 28 other locations · NCT07158242

• Afimkibart (RO7790121) for moderate to severe rheumatoid arthritis after TNF or JAK failure

  This will test whether Afimkibart (RO7790121) works and is safe for people with moderate to severe rheumatoid arthritis who didn't respond to or can't tolerate TNF or JAK inhibitors.

  Recruiting at 65 sites Phase 2 Hoffmann-La Roche · Avondale, Arizona and 64 other locations · NCT07137598

• Inavolisib plus endocrine therapy for early-stage PIK3CA‑mutated ER+ HER2‑ breast cancer

  This trial will test whether adding inavolisib to endocrine therapy (with ribociclib and letrozole) is safe and helps shrink untreated, early-stage PIK3CA‑mutated ER‑positive, HER2‑negative breast cancer before surgery.

  Recruiting at 37 sites Phase 2 Hoffmann-La Roche · Los Angeles, California and 36 other locations · NCT07054190

• Emicizumab prophylaxis for people with Type 3 von Willebrand disease

  This trial will test whether regular emicizumab injections reduce bleeds compared with on-demand standard therapy for people aged 1 month and older with Type 3 von Willebrand disease, while also studying people already on prophylaxis using their prior data.

  Recruiting at 29 sites Phase 3 Hoffmann-La Roche · Sacramento, California and 28 other locations · NCT06998524

• Evaluating a new treatment for advanced solid tumors with RAS mutations

  This study is testing a new treatment called RO7673396 to see if it is safe and effective for people with advanced solid tumors that have RAS mutations.

  Recruiting at 25 sites Phase 1 Hoffmann-La Roche · Duarte, California and 24 other locations · NCT06884618

• Evaluating outcomes of ALK-positive lung cancer patients treated with Alectinib after surgery

  This study is testing if Alectinib can help adults with ALK-positive lung cancer feel better after their surgery.

  Recruiting at 43 sites Hoffmann-La Roche · Zhanjiang, Guangdong and 43 other locations · NCT06862869

• Port Delivery System with ranibizumab refilled every 36 weeks for neovascular (wet) AMD

  This trial tests whether a refillable eye implant that delivers ranibizumab every 36 weeks works and is safe for people with recent neovascular (wet) age-related macular degeneration who responded to prior anti-VEGF injections.

  Recruiting at 63 sites Phase 3 Hoffmann-La Roche · Innsbruck and 63 other locations · NCT06847542

• Gene therapy for Huntington's Disease using SPK-10001

  This study is testing a new gene therapy called SPK-10001 to see if it can safely help people with Huntington's Disease feel better.

  Recruiting at 5 sites Phase 1/2 Hoffmann-La Roche · Boston, Massachusetts and 4 other locations · NCT06826612

• Evaluating a new treatment for active Crohn's disease

  This study is testing a new drug called RO7790121 to see if it can help people with moderate to severe Crohn's disease feel better when other treatments haven't worked.

  Recruiting at 198 sites Phase 3 Hoffmann-La Roche · Dothan, Alabama and 207 other locations · NCT06819891

• Evaluating a new treatment for active Crohn's disease

  This study is testing a new medication for people with moderately to severely active Crohn's disease to see if it helps them feel better compared to a placebo.

  Recruiting at 357 sites Phase 3 Hoffmann-La Roche · Dothan, Alabama and 374 other locations · NCT06819878

• Evaluating Glofitamab with Gemcitabine and Oxaliplatin for Lymphoma

  This study is testing a new combination treatment of glofitamab, gemcitabine, and oxaliplatin for people with relapsed or hard-to-treat lymphoma to see how well it works and if it causes side effects.

  Recruiting at 45 sites Phase 2 Hoffmann-La Roche · Anchorage, Alaska and 52 other locations · NCT06806033

• Divarasib plus pembrolizumab versus pembrolizumab with pemetrexed and platinum chemotherapy for first-line KRAS G12C advanced non-squamous non-small cell lung cancer

  This trial tests whether adding divarasib to pembrolizumab works better than standard pembrolizumab with pemetrexed plus carboplatin or cisplatin for adults with untreated, KRAS G12C-mutant advanced non-squamous non-small cell lung cancer.

  Recruiting at 295 sites Phase 3 Hoffmann-La Roche · Anchorage, Alaska and 298 other locations · NCT06793215

• Evaluating a new treatment for advanced breast cancer

  This study is testing a new combination treatment for people with advanced hormone receptor-positive, HER2-negative breast cancer who have specific genetic mutations to see if it can help them feel better and live longer.

  Recruiting at 239 sites Phase 3 Hoffmann-La Roche · Goodyear, Arizona and 241 other locations · NCT06790693

• Investigating the effects of ocrelizumab on neurofilament levels and patient satisfaction in multiple sclerosis

  This study is testing how the medication ocrelizumab affects certain markers in the blood and how satisfied people with multiple sclerosis feel about their treatment after a year.

  Recruiting at 86 sites Hoffmann-La Roche · Aachen and 92 other locations · NCT06780150

• Evaluating the Accu-Chek SmartGuide CGM for Diabetes Management

  This study is testing if the Accu-Chek SmartGuide continuous glucose monitor can help adults with Type 1 or insulin-dependent Type 2 diabetes manage their blood sugar levels better than traditional self-monitoring methods.

  Recruiting at 19 sites Hoffmann-La Roche · Gdansk and 19 other locations · NCT06704672

• Assessing the impact of Multiple Sclerosis on physical function while providing continued ocrelizumab treatment

  This study is testing how Multiple Sclerosis affects physical function while continuing treatment with the medication ocrelizumab for people who have already been part of related studies.

  Recruiting at 53 sites Phase 3 Hoffmann-La Roche · Pleven and 55 other locations · NCT06675955

• Evaluating Pegozafermin for Liver Disease in Patients with Compensated Cirrhosis

  This study is testing if a new treatment called pegozafermin can improve liver health in people with compensated cirrhosis caused by metabolic issues.

  Recruiting at 298 sites Phase 3 Hoffmann-La Roche · Birmingham, Alabama and 329 other locations · NCT06419374

• Evaluating Pegozafermin for Liver Fibrosis in MASH Patients

  This study is testing if a new medication called pegozafermin can help adults with liver fibrosis caused by metabolic dysfunction-associated steatotic liver disease feel better.

  Recruiting at 335 sites Phase 3 Hoffmann-La Roche · Birmingham, Alabama and 369 other locations · NCT06318169

• Investigating why some breast cancer therapies stop working

  This study is trying to understand why some breast cancer treatments stop working by looking at tumor and blood samples from people with different types of breast cancer.

  Recruiting at 27 sites Phase 4 Hoffmann-La Roche · Anderlecht and 27 other locations · NCT06274515

• Evaluating the effectiveness of baloxavir marboxil for treating influenza in young children

  This study is testing if a new flu medication works well in young children aged 1 to under 12 who have been diagnosed with influenza.

  Recruiting at 20 sites Phase 3 Hoffmann-La Roche · Birmingham, Alabama and 50 other locations · NCT06094010

• Evaluating Glofitamab for Relapsed Mantle Cell Lymphoma

  This study is testing if a new treatment called glofitamab can work better than standard options for people with relapsed mantle cell lymphoma.

  Recruiting at 62 sites Phase 3 Hoffmann-La Roche · Berkeley, California and 82 other locations · NCT06084936

• Evaluating NXT007 for treating severe or moderate Hemophilia A

  This study is testing a new treatment called NXT007 to see if it can safely help boys and men with severe or moderate Hemophilia A manage their condition better.

  Recruiting at 12 sites Phase 1/2 Hoffmann-La Roche · Sacramento, California and 13 other locations · NCT05987449

• Evaluating Inavolisib with Phesgo for Advanced Breast Cancer

  This study is testing if a new combination of inavolisib and Phesgo can help people with advanced breast cancer caused by specific genetic changes feel better after their initial treatment.

  Recruiting at 79 sites Phase 3 Hoffmann-La Roche · Gilbert, Arizona and 191 other locations · NCT05894239

• Continuation of treatment for cancer patients from previous studies

  This study is testing if cancer patients who have been part of earlier research can continue receiving treatment with new medications to see if it helps them keep feeling better.

  Recruiting at 66 sites Phase 3 Hoffmann-La Roche · Charleroi and 84 other locations · NCT05862285

• Evaluating divarasib with other cancer therapies for advanced lung cancer with a KRAS mutation

  This study is testing if a new cancer drug called divarasib, when combined with other treatments, can help people with advanced lung cancer that has a specific KRAS mutation feel better and improve their outcomes.

  Recruiting at 57 sites Phase 1/2 Hoffmann-La Roche · Duarte, California and 70 other locations · NCT05789082

• Inavolisib plus fulvestrant vs alpelisib plus fulvestrant in PIK3CA-mutated HR-positive HER2-negative breast cancer

  This study tests whether inavolisib with fulvestrant works better or as well as alpelisib with fulvestrant for people with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer who have progressed after CDK4/6 inhibitor therapy.

  Recruiting at 5 sites Phase 3 Hoffmann-La Roche · Greenbrae, California and 209 other locations · NCT05646862

• Evaluating treatments for multiple myeloma

  This study is testing different combinations of treatments for people with multiple myeloma to see which ones are safe and effective, especially for those with specific challenges or who have already tried other therapies.

  Recruiting at 14 sites Phase 1/2 Hoffmann-La Roche · Randwick, New South Wales and 15 other locations · NCT05583617

• Evaluating Glofitamab for Pediatric and Young Adult Patients with Relapsed B-Cell Non-Hodgkin Lymphoma

  This study is testing a new treatment called glofitamab, alone and with standard chemotherapy, to see if it helps kids and young adults with relapsed B-cell non-Hodgkin lymphoma feel better.

  Recruiting at 30 sites Phase 1/2 Hoffmann-La Roche · Birmingham, Alabama and 29 other locations · NCT05533775

• Evaluating satralizumab for children with neuromyelitis optica spectrum disorder

  This study is testing a new treatment called satralizumab to see if it helps children aged 2 to 11 with neuromyelitis optica spectrum disorder feel better and stay safe.

  Recruiting at 13 sites Phase 3 Hoffmann-La Roche · Denver, Colorado and 13 other locations · NCT05199688

• Evaluating mosunetuzumab alone and with venetoclax for chronic lymphocytic leukemia

  This study is testing a new treatment called mosunetuzumab, alone and with another drug called venetoclax, to see how well it works for people with chronic lymphocytic leukemia that hasn't responded to other treatments.

  Recruiting at 24 sites Phase 1 Hoffmann-La Roche · Rochester, Minnesota and 30 other locations · NCT05091424

• Evaluating Obinutuzumab for Lupus Nephritis in Adolescents

  This study is testing if a medication called obinutuzumab can help teenagers with lupus nephritis feel better and improve their kidney health.

  Recruiting at 33 sites Phase 2 Hoffmann-La Roche · Loma Linda, California and 43 other locations · NCT05039619

• Evaluating targeted therapies for metastatic colorectal cancer

  This study is testing if targeted therapies and immunotherapy can help people with metastatic colorectal cancer who have certain biomarkers in their tumors.

  Recruiting at 56 sites Phase 1 Hoffmann-La Roche · Birmingham, Alabama and 83 other locations · NCT04929223

• Evaluating treatment combinations for advanced breast cancer

  This study is testing different combinations of treatments for people with advanced breast cancer to see which ones work best and are safe.

  Recruiting at 29 sites Phase 1/2 Hoffmann-La Roche · Duarte, California and 31 other locations · NCT04802759

• Long-term evaluation of a delivery system for eye treatment in age-related macular degeneration

  This study is testing a new delivery system for eye treatment to see if it is safe and effective for people with a specific type of age-related vision loss.

  Recruiting at 71 sites Phase 3 Hoffmann-La Roche · Phoenix, Arizona and 164 other locations · NCT03683251

• Evaluating treatment combinations for advanced breast cancer

  This study is testing different combinations of treatments for people with advanced breast cancer to find out which ones work best and are safe.

  Recruiting at 39 sites Phase 1/2 Hoffmann-La Roche · Duarte, California and 54 other locations · NCT03424005

Quick answers

How many clinical trials run by Hoffmann-La Roche are recruiting right now?

78, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 61 countries. The most sites are in United States (54 trials), Spain (41 trials), United Kingdom (40 trials), Italy (36 trials), Germany (35 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 34, Phase 2: 15, Phase 1/2: 9, Phase 1: 8. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →